Published in Ann Rheum Dis on November 01, 1991
Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag (2010) 1.19
Commentary: Iloprost for cholesterol emboli syndrome. BMJ (2002) 0.92
A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol (2009) 0.86
Pulmonary hypertension: its assessment and treatment. Thorax (1999) 0.79
Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis (1995) 0.78
[Evidence-based therapy of Raynaud's syndrome]. Z Rheumatol (2006) 0.76
Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Res Ther (2013) 0.75
Digital artery occlusion secondary to plastic shopping bag trauma. Ann R Coll Surg Engl (2007) 0.75
Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions. Rheumatol Int (2004) 0.75
A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost. Clin Rheumatol (1997) 0.75
Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001-2012. Rheumatol Int (2015) 0.75
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet (1983) 1.94
Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J (1978) 1.51
Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum (1984) 1.35
Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet (1982) 1.34
Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med (1980) 1.24
Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol (1982) 1.17
Prostaglandin E1 vasospastic disease and thermography. Ann Rheum Dis (1985) 1.14
Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J (1987) 1.13
Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum (1984) 1.12
Successful treatment of Raynaud's Syndrome with prostacyclin. Thromb Haemost (1981) 1.00
Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol (1988) 0.97
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis (1988) 0.93
Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function. J Lab Clin Med (1987) 0.90
Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins (1986) 0.90
Defective fibrinolytic response in atherosclerotic patients--effect of iloprost and its possible mechanism of action. Thromb Haemost (1988) 0.87
Uses and abuses of analysis of variance. Br J Clin Pharmacol (1983) 0.84
Nifedipine and Raynaud's phenomenon. Ann Intern Med (1981) 0.83
Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon. Lancet (1985) 0.82
Abnormal biochemical and cellular parameters in the blood of patients with Raynauds phenomenon. Scott Med J (1987) 0.81
Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome. Prostaglandins Leukot Med (1985) 0.81
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg (2007) 14.17
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg (2006) 10.79
Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg (2000) 5.50
How to ensure that guidelines are effective. BMJ (1995) 4.31
Oxpentifylline treatment of venous ulcers of the leg. BMJ (1990) 3.75
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
A simple method for measuring erythrocyte deformability. J Clin Pathol (1976) 2.81
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) (1983) 2.63
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Impaired red cell deformability in peripheral vascular disease. Lancet (1976) 2.40
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet (1991) 2.37
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum (1994) 2.30
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Serological findings in patients with "ANA-negative" systemic lupus erythematosus. Medicine (Baltimore) (1981) 2.27
Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med (1982) 2.26
Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. N Engl J Med (1983) 2.24
Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J (1973) 2.17
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Abnormalities in the mechanical properties of red blood cells caused by Plasmodium falciparum. Blood (1989) 2.12
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis (1993) 2.05
Leukocytes and the risk of ischemic diseases. JAMA (1987) 2.03
External fixation versus conservative treatment for distal radial fractures in adults. Cochrane Database Syst Rev (2007) 2.03
Cutting waiting lists. BMJ (1991) 2.02
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Illiteracy in rheumatoid arthritis patients as determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) score. Rheumatology (Oxford) (2002) 2.00
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol (1985) 1.92
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone. Lancet (1990) 1.88
Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis (1997) 1.87
Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed) (1988) 1.85
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Percutaneous pinning for treating distal radial fractures in adults. Cochrane Database Syst Rev (2007) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Clinical significance of blood viscosity. Ann R Coll Surg Engl (1970) 1.75
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol (1990) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Influence of blood viscosity on blood flow and the effect of low molecular weight dextran. Br Med J (1971) 1.72
Does second-line therapy affect the radiological progression of rheumatoid arthritis? Ann Rheum Dis (1984) 1.69
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis (2004) 1.69
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Is hyperviscosity a treatable component of diabetic microcirculatory disease? Lancet (1977) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1986) 1.64
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Serologic subsets in systemic lupus erythematosus: an examination of autoantibodies in relationship to clinical features of disease and HLA antigens. Arthritis Rheum (1980) 1.62
Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs. Am J Gastroenterol (1991) 1.57
Surgical interventions for treating distal radial fractures in adults. Cochrane Database Syst Rev (2003) 1.57
Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol (1985) 1.56
Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis (1985) 1.56
Factor VIII related antigen in connective tissue disease patients and relatives. Br J Rheumatol (1990) 1.55
Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) (1986) 1.55
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Misoprostol in patients taking non-steroidal anti-inflammatory drugs. BMJ (1995) 1.54
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
Vitamin D deficiency, spontaneous fractures, and osteopenia in rheumatoid arthritis. Br Med J (1974) 1.53
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) (1985) 1.51
A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question? Ann Rheum Dis (1985) 1.50
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Stress arteriography. Lancet (1973) 1.49
Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis (1985) 1.49
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
Sjögren's syndrome: association with type-1 diabetes mellitus. Br J Rheumatol (1989) 1.48
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine. Br J Rheumatol (1987) 1.45
Surgical interventions for treating distal radial fractures in adults. Cochrane Database Syst Rev (2001) 1.44
Infrared thermography: what is its place in rheumatology in the 1990s? Br J Rheumatol (1992) 1.44